4D Molecular Therapeutics

FDMTPhase 3

Emeryville, United States4dmoleculartherapeutics.com

4D Molecular Therapeutics is a visionary gene therapy company leveraging its proprietary Therapeutic Vector Evolution platform to design customized adeno-associated viral (AAV) vectors for specific diseases. The company's most advanced assets target retinal conditions, with 4D-150 showing promising Phase 2 data in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), significantly reducing the need for frequent anti-VEGF injections. With a strategic focus on retina and pulmonology, bolstered by significant partnerships and non-dilutive funding, 4DMT is positioned to advance multiple programs into late-stage development and potentially bring transformative one-time treatments to patients.

Market Cap

$439.2M

Focus

RNA & Gene Therapy

FDMT · Stock Price

USD 8.616.52 (-43.09%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Therapeutic Vector Evolution (TVE) platform that uses directed evolution to engineer customized adeno-associated viral (AAV) vectors with enhanced tissue targeting, transduction efficiency, and immune-evasion properties for specific diseases.

Pipeline Snapshot

9 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Neovascular Age-Related Macular Degeneration (nAMD)	Phase 3
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Macular Neovascularization Secondary to Age-Related Macular Degeneration	Phase 3
4D-150 IVT + Aflibercept IVT	Diabetic Macular Edema	Phase 2
4D-710	Cystic Fibrosis Lung	Phase 2
4D-150 IVT + Aflibercept IVT	Neovascular (Wet) Age-Related Macular Degeneration	Phase 1/2

Opportunities

The primary opportunity is capturing a large share of the multi-billion dollar wet AMD and DME markets with a one-time, durable therapy that eliminates frequent injections.

Success would also validate the vector platform, enabling expansion into other high-value therapeutic areas like cardiology and creating significant partnership and licensing potential.

Risk Factors

Key risks include clinical trial failure in Phase 3, intense competition from other gene therapy developers in retina, potential safety issues with AAV vectors, challenges in scaling manufacturing, and dependence on partnership funding to reach commercialization.

Competitive Landscape

4DMT faces direct competition in retinal gene therapy from Regenxbio (RGX-314) and others. Its main differentiation is its proprietary evolved vector platform (R100) and a dual-transgene payload designed for potency and durability. In cystic fibrosis, it competes with next-generation therapies, differentiating via its aerosolized delivery and engineered C102 vector for lung transduction.

Publications

Patents

Pipeline